UPDATE 1-Johnson & Johnson to buy Actelion for $30 bln

UPDATE 1-Johnson & Johnson to buy Actelion for $30 bln


Jan 26 Swiss biotech company Actelion said on Thursday it had agreed to be purchased by Johnson & Johnson in a $30 billion all-cash deal, following weeks of speculation a deal was imminent. The offer to acquire all of the outstanding shares of Actelion for $280 per share, payable in U.S. dollars, was unanimously approved by the boards of directors of both companies, Actelion and Johnson & Johnson said in a joint statement.



from Biotech News